With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
August 24, 2017. Killing hepatic tumor burden without killing teetering liver functions can be a hard line to toe. While reported local control with stereotactic body radiotherapy (SBRT) is promising, most trials exclude patients with underlying liver disease--arguably one of the most relevant real-world cohorts. Enter adaptive liver stereotactic body radiation (SBRT) tailored to each individual’s mid-treatment liver function as determined via plasma retention fraction of indocyanine green (ICG). A Phase 2 trial published this month in JAMA Onc explores the safety and effectiveness of adaptive SBRT to previously-treated intrahepatic cancers. Based on ICG assessment after 3 of 5 planned SBRT treatments of 12 Gy, dose was de-escalated in 45% of tumors...leaving over half getting the full planned 60 Gy (well above commonly-used conservative doses for previously treated livers). Safety and local control (95%) at 2 years were excellent, though there was overall survival (36%) left to be desired. Bottom line: this shows that with a little extra tailoring, maximal tumor control and maximal patient safety need not be mutually exclusive.